Introduction
Intracranial pure germinoma is a radiosensitive disease and more than 90 % of the patients are curable by radiation therapy (RT) [1, 2] . Therefore, prognosis for this disease is usually good. Cranio-spinal irradiation (CSI) followed by cranial boost, or only cranial irradiation with total doses of 40-50 Gy has been commonly used for treatment [3] . As the majority of the patients with this disease are children or teenagers, a large irradiated volume or high radiation dose may cause late adverse effects such as growth disturbances or brain dysfunction. Germ cell tumors are also known to be chemo-sensitive and treatment regimens with chemotherapy alone were examined in some trials [4, 5] . The initial response with chemotherapy was excellent, but considerable high rates of recurrence were observed. Consequently, RT was thought to be essential for maintaining the cure of this disease even after achieving complete response by chemotherapy. On the other hand, total dose and target volume of RT might be modified when RT is used with chemotherapy. Reduced dose RT regimens of 24 Gy for 12 fractions were examined from the 1990s and promising results were reported [6] , but optimal treatments are still unknown. When germinoma had not disseminated to the spinal canal and had shown good response to induction chemotherapy, reductions of total dose and radiation fields might be reasonable. This study evaluated the results of 24 Gy of cranial RT without spinal irradiation with the use of induction chemotherapy. Treatment regimens were approved by the on-site tumor board.
Abstract
Purpose To evaluate the efficacy of sequential chemoradiotherapy (CRT) for intracranial germinoma by long-term follow-up. Materials and methods We retrospectively evaluated 23 consecutive intracranial germinoma patients without spinal dissemination, who had been treated by sequential CRT. All patients except for one were biopsied or surgically resected before treatment and all patients received both cranial and spinal magnetic resonance imaging. Three cycles of induction chemotherapy composed of etoposide and platinum agents were administered. The prescription of radiotherapy was 24 Gy per 12 fractions. No patients received spinal irradiation. Results All patients accomplished CRT and achieved complete remission. No severe acute and late toxicities were observed. Median follow-up time was 11.8 years. The 5-and 10-year overall survival rates were 100 and 100 %, and relapse-free survival rates were 96 and 89 %, respectively. Three patients developed intracranial recurrence and all of them were successfully salvaged by additional CRT. All patients were alive without disease at final follow-up. Conclusion Treatment of 24 Gy of sequential CRT for intracranial germinoma might be promising as an alternative to radiotherapy alone. Spinal irradiation may not be
Materials and methods

Patient characteristics
Twenty-three intracranial germinoma patients treated by sequential chemoradiotherapy (CRT) between January 1996 and December 2006 were retrospectively evaluated (Table 1) . Median age at diagnosis was 13 years (range 9-38 years). There were 18 males and five females. Cranial and spinal MRI were used for initial evaluation in all patients. All patients, except one who was diagnosed only by MRI, received biopsy or surgical resection before CRT. Twenty patients were diagnosed as having pure germinoma and two patients had germinoma with syncytiotrophoblastic giant cells (STGC). Primary tumor sites were: pineal gland in 11 patients (48 %); neurohypophysial in six (26 %); basal ganglia in two (9 %); both pineal gland and neurohypophysial in two (9 %); and both basal ganglia and neurohypophysial in two (9 %), respectively. Multiple intracranial lesions including ventricular dissemination were identified on MRI in nine patients (39 %). Maximum tumor size of the main lesions was between 0.7 and 4 cm (median, 2.5 cm) in 15 evaluable patients. Ten patients (56 %) had hydrocephalus at diagnosis and four of them received a third ventriculostomy. Spinal dissemination was not detected on MRI in any of the patients. Median Karnofsky performance status (KPS) at diagnosis was 80 (range 60-100). Six patients (26 %) presented diplopia and three patients (13 %) had narrowed visual fields. Endocrine dysfunctions were detected in 13 patients (57 %). Spinal fluid cytology was not positive in any of the patients. Serum human chorionic gonadotropin-beta (hCG-β) was elevated in eight of 18 evaluable patients (44 %). Elevation of alphafetoprotein (AFP) was not detected in all of the 18 evaluable patients. Patient characteristics are summarized in Table 1 .
Treatments
Chemotherapy
Three cycles of induction chemotherapy composed of etoposide and platinum agents were administered in all patients ( Table 2 ). The original regimen (CE regimen) was composed of etoposide infusion (150 mg/m 2 /day on days 1, 2, 3) and carboplatin (600 mg/m 2 on day 1). Between 1998 and 2003, the chemotherapy regimen was modified to increase the intensity. The modified regimen (PEI regimen) was composed of three cycles of induction chemotherapy with etoposide infusion (60 mg/m 2 /day on days 1, 2, 3), cisplatin (20 mg/m 2 /day on days 1, 2, 3) and ifosfamide (900 mg/m 2 on day 1) and six cycles of maintenance chemotherapy with carboplatin infusion (600 mg/m 2 on day 1) and etoposide tablets (100 mg/ m 2 /day on days 1, 2, 3) after the completion of RT. We returned to the original (CE) regimen after 2003 and stopped administering maintenance chemotherapy after 2005 to avoid prolonging myelosuppression, increasing the risk of a second malignancy and too long a treatment schedule. After the second course of induction chemotherapy, cranial MRI was performed in every patient for evaluation of initial response.
One patient treated by the CE regimen used cisplatin (20 mg/m 2 /day on days 1, 2, 3) instead of carboplatin (600 mg/m 2 on day 1). Two of the eight patients who were to be treated by PEI regimen did not receive ifosfamide on the third course because of myelosuppression. A 37-yearold male patient who received RT in 2001 was treated with CE regimen and without maintenance chemotherapy. All other patients accomplished the planned three courses of chemotherapy and subsequent RT.
All patients except one achieved complete response after the second course of chemotherapy as evaluated by MRI. Residual tumor was detected in one patient who was confirmed by biopsy and received two courses of PEI regimen. Craniotomy and total tumor resection was performed to confirm the histology. However, the histopathology was consistent with the initial diagnosis of pure germinoma, and the patient continued to receive the third course of chemotherapy and planned RT according to the initial regimen.
Radiotherapy
One to 2 weeks after completion of the third course of induction chemotherapy, cranial RT was started. Median duration time between the initiation of induction chemotherapy and the start of RT was 70 days (range 61-103).
A three-dimensional RT planning system was used for target delineation and dose calculation. Gross tumor volume (GTV) was defined as enhanced lesions on pretreatment MRI. For the initial five patients treated before 1998, clinical target volume (CTV) was defined as local with 2-to 3-cm margins on GTV. A larger CTV, including the whole ventricle plus 0.5-to 1.5-cm margins was applied after 1998 ( Fig. 1) . Whole brain, i.e. whole cranial irradiation, was used for six patients who had basal ganglia tumors or who had hydrocephalus before treatment. Anatomical barriers such as bony structures were considered to delineate the CTV. The planning target volume (PTV) was made with a 0.5-cm margin around the CTV. A linear accelerator of 4 or 6 MV energy was used for irradiation. Twenty-four gray in 12 fractions were administered at the isocenter located in the center of the CTV. One patient was treated with a 1.8-Gy fractionation size (total 23.4 Gy in 13 fractions). All the other patients completed the prescribed cranial irradiation with total dose of 24 Gy. Spinal irradiation was not used in any patients as an initial treatment. Median duration time of RT was 16 days (range 15-25).
Evaluation and follow-up
Blood and MRI examination was done at the completion of all planned treatments and every 6-12 months thereafter. In the case of recurrence, additional evaluation was done according to the initial diagnostic procedures. The survival time was calculated using the Kaplan-Meier method.
Results
No severe adverse events were encountered during RT. Any residual disease or new lesions were not detected on MRI after RT. Median follow-up time from the initiation of treatment was 11.8 years (range 6.3-18.3 years). All patients were alive without disease at the time of the latest follow-up. The 5-and 10-year overall survival rates were 100 and 100 %, respectively. The 5-and 10-year relapsefree survival rates were 96 and 89 %, respectively (Fig. 2) .
Three patients developed intracranial recurrence. Two of them had an initial tumor in the pineal gland or neurohypophysial area. No intracranial or spinal dissemination was detected on MRI at initial treatment. Surgical interventions were done and pure germinoma was revealed on pathology. Following induction chemotherapy, localized CTVs and 4 beams with a small field size of 5 × 5 cm were used for their RT. They did not receive maintenance chemotherapy. Follow-up MRI revealed tumor recurrences outside the irradiated volume at 1.8 and 13.6 years. Their primary lesions were controlled and dissemination to the spinal axis was not found. A biopsy was performed on each patient and the histological evaluation revealed a pure germinoma. The other patient confirmed as having neurohypophysial pure germinoma received whole ventricle irradiation and 6 cycles of maintenance chemotherapy. An asymptomatic periventricular tumor recurrence was detected inside the CTV by follow-up MRI at 8.4 years. This patient did not receive a biopsy at the time of recurrence. All three patients started salvage treatment just after the diagnosis of recurrence. Additional chemotherapy with the PEI regimen followed by administering 30.6 or 36 Gy of CSI was administered to them. After completion of the CSI, no residual tumor was detected in these three patients. Up to the final follow-up from salvage treatment (3.2, 3.5 and 16.5 years), no new recurrence was detected. However, the first patient had developed hormonal deficiency with a need to receive substitution therapy. An enhanced MRI of the second patient treated with localized CTV for a neurohypophysial tumor are shown in Fig. 3 . The other 20 patients did not develop recurrences up to the final follow-up. Table 3 summarizes the performance status and clinical symptoms before and after treatment. Karnofsky performance status (KPS) did not worsen after treatment in any of the patients except one who experienced recurrence and received salvage treatment. Nine patients had visual dysfunction (six patients with double vision and three patients with narrowing fields) at diagnosis. All nine patients had improved visual symptoms after treatment. No visual problems were observed in the other patients before or after treatment. Thirteen patients who initially had endocrine dysfunction continued to receive hormonal substitution therapy after treatment. One patient who experienced recurrence and received salvage treatment then developed hypopituitarism. Secondary malignancies were not detected in any of the patients up to the final follow-up. Abnormal behavior was observed in one patient at diagnosis and the symptom was not improved after treatment. Severe neurocognitive problems were not newly detected in any other patients.
Discussion
Traditionally, RT using CSI can cure more than 90 % of intracranial germinoma patients. A prescribed total cranial dose of 40-50 Gy has been frequently used for RT alone and long-term overall survival was reported from 90 to 100 % [1] [2] [3] [13] [14] [15] .
On the other hand, there are some controversies about the target volume settings such as adopting CSI [12] [13] [14] . Schoenfeld et al. [10] reported the outcomes of 21 Gy for CSI, 30 Gy to the whole ventricle and 49.5 Gy to the tumor by RT alone in which no patients developed dementia or skeletal growth problems while achieving a 94 % diseasefree ratio at 7 years. Cho [11] analyzed the patients treated by CSI without chemotherapy and recommended 19.5 Gy as the spinal dose. In contrast, Shikama et al. [16] retrospectively analyzed 180 cases from multi-institutions and concluded that spinal irradiation did not contribute to a favorable event-free survival. Shirato et al. [17] analyzed the RT fields and recurrence patterns of patients with intracranial germinoma and reported that six relapses were observed in 18 patients who were treated with the minimum margins around the detectable tumor. Ogawa et al. [18] reported that large sized or multifocal intracranial disease were risk factors for spinal recurrence but salvage treatment combined with spinal RT and chemotherapy were effective in cases of spinal recurrence. Patients treated before the 1990s did not receive precise spinal evaluation by MRI. Some patients had spinal dissemination which was not detected by clinical examination or X-ray computed tomography. Prophylactic spinal irradiation might be reasonable for these patients. Spinal MRI provided much more information [19] after the mid 1990s, and it was then appropriate to change target volumes of RT according to the risk of dissemination. In our series, spinal irradiation was not adopted on the basis of MRI evaluation.
Germinoma is also a chemo-sensitive tumor and high response rates and good outcomes have been reported by combinations of chemotherapy and RT. Reported treatments and outcomes of intracranial germinoma are summarized in Table 4 . When RT combined with chemotherapy is used for chemo-and radio-sensitive tumors, it may be appropriate to reduce the total dose of RT. [8, 9] .
Initially, local CTV with 2-to 3-cm margins on GTV was adopted [6] . The prescribed dose was 24 Gy in 12 fractions. After experiencing intracranial recurrence just beside the irradiated area in one patient treated with a local field, and after obtaining information about the risk of narrow fields [17] , we decided to enlarge the CTV from local to the whole ventricle or whole brain, but we did not change the prescribed dose. One intracranial recurrence inside the PTV was observed in our series. For this patient, the primary site was the pineal gland and multiple lesions were not detected before initial treatment. Histology showed pure germinoma, and beta HCG was not elevated. After achieving complete remission by induction chemotherapy, the patient received whole ventricle irradiation. We could not find out the risk factors of recurrence inside PTV. However, no patients developed spinal recurrence. Limiting CTV to the cranial area and omitting spinal irradiation might be adequate for patients who have no spinal dissemination on MRI and have been treated with CRT.
According to the retrospective studies [16, 18] , spinal recurrence occurred only in less than 5 % of the patients who did not receive chemotherapy but received cranial irradiation, including the primary site. Spinal irradiation may also not be necessary for patients without chemotherapy who had no dissemination on spinal MRI.
By administering chemotherapy, reducing the total dose of radiotherapy might be reasonable, but initial target volume setting had better be the same for intracranial germinoma treated by chemoradiotherapy or radiotherapy alone.
The prevention of late adverse events while maintaining high cure rates are important issues in the treatment of this disease which generally has a good prognosis. Hypothalamic-pituitary deficiency depends on the dose and volume of irradiation [20, 21] . The incidence of late endocrine dysfunction is reported to be between 0 and 85 % after cranial RT [22] . The incidence of hormonal disorders in pediatric brain tumor patients at diagnosis is not low [24] . As endocrine dysfunction may continue through life and patients may need substitution therapy for a long time, the reduction of this risk is important. Ogawa et al. [23] reported that hormonal replacement therapy was newly required after RT in 4 % of surviving patients and all of them had neurohypophysial tumors. Hypopituitarism was observed in 61 % of our series at final follow-up, but all patients except one had some type of disorder at diagnosis. Treatment itself may not cause severe adverse events in the endocrine system in our regimen. Of course, precise evaluations and adequate interventions before, during and after the treatment are essential.
Cranial RT for pediatric patients also affects neurocognitive functions [25, 26] . Cognitive dysfunctions are reported as late adverse events, especially after high-dose RT [7] . The risk to intellectual development is associated not only with the dose and target volume of RT but with the patient's age [27] . We have not experienced any newly developed mental retardation or cognitive dysfunction after treatment. A relatively low dose RT in later childhood or adolescence (aged 9 years old or more) may not severely affect neuro-cognitive function, even when used with sequential chemotherapy.
The optimal combination of RT and chemotherapy for intracranial germinoma is still unknown. A direct comparison of RT alone with CRT is limited, and a randomized trial is difficult to conduct for this disease with good prognosis and rare occurrence. RT alone might still have an important role for this disease and CRT may also become a reasonable choice. Careful and long-term examination of adverse events will provide useful information for choosing treatment.
In conclusion, 24 Gy of sequential CRT for intracranial germinoma might be a promising treatment as an alternative for RT alone. Spinal irradiation may not be necessary for patients who have no spinal dissemination on MRI and who have been treated with CRT.
